Nov 13, 2012 by Brenton Flynn and Max MacalusoDown 14%, FDA Concerns Crush NektarWhy FDA concerns hurt Nektar on Monday.
Nov 13, 2012 by Brenton Flynn and Max MacalusoCelgene Hits the Mark With AbraxaneAbraxane looks poised to receive another indication.
Nov 12, 2012 by Brenton Flynn100%! Gilead's Perfect Results One-Up AbbottWorking on the weekend never felt this good.
Nov 9, 2012 by Brenton Flynn and Max MacalusoQuestcor Pharmaceuticals: Likes and DislikesThe pros and cons of this controversial biotech.
Nov 9, 2012 by Brenton FlynnMAKO Surgical: Likes and DislikesThere's a lot of excitement, but is it time to buy?
Nov 8, 2012 by Brenton FlynnManagement Is Buying at Questcor, Should You?A new generic competitor lurks abroad.
Nov 8, 2012 by Brenton Flynn2 Key Stats From MAKO's EarningsResults surpassed this analyst's expectations in one regard.
Nov 7, 2012 by Brenton FlynnHot Off the Press: MAKO Surgical's Mixed QuarterMAKO reports third quarter results
Nov 7, 2012 by Brenton Flynn2 Must-Watch Stats on MAKO Surgical's EarningsInvestors will focus in on two metrics at MAKO.
Nov 7, 2012 by Brenton FlynnHot Off the Press: Spectrum Soars Higher After EarningsSpectrum's third quarter results sail past estimates
Nov 7, 2012 by Brenton FlynnHot Off the Press: Pfizer Goes After AbbottTwo health care news items to watch in today's trading.
Nov 7, 2012 by Brenton FlynnHot Off the Press: Obesity Stocks and a Huge FDA ApprovalTwo health care news items to watch in today's trading.
Nov 6, 2012 by Brenton Flynn and Dave WilliamsonIs Danger Lurking in Dendreon's Future?What investors need to know.
Nov 6, 2012 by Brenton FlynnHot off the Press: VIVUS Earnings ReportThe first-mover in obesity drugs reports financial results
Nov 5, 2012 by Brenton Flynn and Max MacalusoA Romney Win Will Bolster These StocksHow the election's victor will hit the health care sector.
Nov 5, 2012 by Brenton Flynn and Max MacalusoObama Victory: What Stocks WinHow the election's victor will hit the health care sector.
Nov 5, 2012 by Brenton Flynn and Max MacalusoToday's Big Biotech LoserThe numbers are nice, so why the slide?
Nov 5, 2012 by Brenton Flynn and Max MacalusoThe Dirty Details Behind Pharmacyclics' SlideThe numbers were good, so why the slide?
Nov 5, 2012 by Brenton Flynn and Max MacalusoWhat's Behind BioMarin's Surge?Phase 3 results are making the stock pop.
